Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Down 96.3% in March

Jaguar Health, Inc. (NASDAQ:JAGX) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 35,700 shares, a decrease of 96.3% from the February 28th total of 953,100 shares. Based on an average daily volume of 22,800 shares, the short-interest ratio is presently 1.6 days. Approximately 0.3% of the company’s shares are sold short.

Jaguar Health Trading Down 5.2 %

Shares of JAGX stock traded down $0.28 during trading hours on Wednesday, hitting $5.13. 52,850 shares of the company were exchanged, compared to its average volume of 27,889. The company has a 50 day simple moving average of $17.15 and a two-hundred day simple moving average of $23.55. The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.36 and a current ratio of 1.84. Jaguar Health has a fifty-two week low of $4.90 and a fifty-two week high of $540.00.

Institutional Investors Weigh In On Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Virtu Financial LLC acquired a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned approximately 0.22% of Jaguar Health at the end of the most recent reporting period. 12.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Jaguar Health in a report on Thursday, March 20th. They issued a “hold” rating for the company.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.